AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15181577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 439
Study 11434846 — intervention group
Group type: EXPERIMENTAL
Intervention: Otikon Otic Solution (naturopathic herbal extract)
Number of subjects: 103
Study 11434846 — intervention group
Group type: COMPARATOR
Intervention: Anaesthetic ear drops (containing ametocaine and phenazone)
Number of subjects: 103
Study 9517682 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered bupivacaine warmed to 37 degrees C
Number of subjects: 40
Study 9517682 — intervention group
Group type: COMPARATOR
Intervention: Room temperature buffered bupivacaine (20 degrees)
Number of subjects: 40
Study 9517682 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered bupivacaine at room temperature
Number of subjects: 40
Study 9517682 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered bupivacaine warmed to 37 degrees C
Number of subjects: 40
Study 9517682 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed bupivacaine to 37 degrees C
Number of subjects: 40
Study 8281886 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet and physical training (1 h twice weekly and daily bicycle ergometry for 30 min)
Number of subjects: 36
Study 8281886 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical training and low-fat diet based on own initiative)
Number of subjects: 36
Study 2815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole therapy
Number of subjects: 0
Study 2815173 — intervention group
Group type: COMPARATOR
Intervention: Mechanical local therapy
Number of subjects: 0
Study 31154635 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who planned their messages
Number of subjects: 100
Study 31154635 — intervention group
Group type: COMPARATOR
Intervention: Participants who did not plan their messages
Number of subjects: 100
Study 31154635 — intervention group
Group type: COMPARATOR
Intervention: Participants (both planning and distraction conditions)
Number of subjects: 100
Study 31199291 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as Usual plus Videoconferencing (TAU-VC)
Number of subjects: 38
Study 31199291 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 38
Study 28495863 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble urokinase plasminogen activator receptor >11,633 pg/ml (third tertile)
Number of subjects: 1175
Study 28495863 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of soluble urokinase plasminogen activator receptor to a risk factor model
Number of subjects: 1175
Study 25400106 — intervention group
Group type: COMPARATOR
Intervention: 0% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23
Study 25400106 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23
Study 25400106 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% L-arabinose in meal A (sucrose and starch from wheat flour)
Number of subjects: 23
Study 25400106 — intervention group
Group type: COMPARATOR
Intervention: 0% L-arabinose in meal B (starch from wheat flour)
Number of subjects: 23
Study 25400106 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% L-arabinose in meal B (starch from wheat flour)
Number of subjects: 23
Study 25400106 — intervention group
Group type: COMPARATOR
Intervention: Liquid meal with maltose and 0% L-arabinose
Number of subjects: 23
Study 25400106 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid meal with maltose and 20% L-arabinose
Number of subjects: 23
Study 23497463 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in depression screening and routine use of depression screening for at least 6 months (Intervention group).
Number of subjects: 3737
Study 23497463 — intervention group
Group type: COMPARATOR
Intervention: Usual management of depression (Control group).
Number of subjects: 3737
Study 21199857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-dose varicella vaccination
Number of subjects: 24488
Study 18448495 — intervention group
Group type: EXPERIMENTAL
Intervention: bosentan
Number of subjects: 30
Study 18448495 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 16458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 28
Study 16458964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost-timolol
Number of subjects: 28
Study 14769716 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium-rich foods (diet)
Number of subjects: 48
Study 14769716 — intervention group
Group type: COMPARATOR
Intervention: Potassium chloride pills (medication)
Number of subjects: 48
Study 11740309 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN (evaporative polyester fabric)
Number of subjects: 8
Study 11740309 — intervention group
Group type: EXPERIMENTAL
Intervention: COT (traditional cotton fabric)
Number of subjects: 8
Study 11740309 — intervention group
Group type: COMPARATOR
Intervention: S‐N (seminude)
Number of subjects: 8
Study 8988937 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 12866
Study 8988937 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 12866
Study 8406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (3, 1 or 0.5 micrograms/kg body wt)
Number of subjects: 9
Study 8406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (3 micrograms/kg body wt)
Number of subjects: 9
Study 8406350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte-macrophage colony-stimulating factor (0.5 to 1 microgram/kg body wt)
Number of subjects: 9
Study 8406350 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 MU interferon-alpha 2b (in combination with GM-CSF)
Number of subjects: 9
Study 2446054 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20‐80 mg daily)
Number of subjects: 20
Study 2446054 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa (500‐2000 mg daily)
Number of subjects: 20
Study 31839432 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 253
Study 31839432 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy in normal BMI and clinical stage IVA disease
Number of subjects: 253
Study 31839432 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study 31429794 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab 2 mg/kg + methotrexate (MTX)
Number of subjects: 592
Study 31429794 — intervention group
Group type: COMPARATOR
Intervention: Placebo + methotrexate (MTX)
Number of subjects: 592
Study 28800444 — intervention group
Group type: EXPERIMENTAL
Intervention: New Forest Parenting Programme (NFPP)
Number of subjects: 164
Study 28800444 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping the Noncompliant Child (HNC)
Number of subjects: 164
Study 28800444 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 164
Study 25224125 — intervention group
Group type: EXPERIMENTAL
Intervention: neuro-music therapy (counseling plus eight 50-minute sessions of individualized music therapy)
Number of subjects: 290
Study 25224125 — intervention group
Group type: COMPARATOR
Intervention: Counseling (50-minute individualized personal instruction)
Number of subjects: 290
Study 23475018 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program (4 weeks)
Number of subjects: 606
Study 23475018 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising group (control)
Number of subjects: 606
Study 21595978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored, iterative, printed dietary feedback (TF)
Number of subjects: 0
Study 21595978 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group nutrition education sessions (GE)
Number of subjects: 0
Study 21595978 — intervention group
Group type: COMPARATOR
Intervention: Wait-listed control (C)
Number of subjects: 0
Study 19191657 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 0
Study 19191657 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted atazanavir
Number of subjects: 0
Study 19191657 — intervention group
Group type: COMPARATOR
Intervention: Boosted protease inhibitor therapy (control)
Number of subjects: 0
Study 16846509 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 month clinical weight loss program
Number of subjects: 144
Study 16846509 — intervention group
Group type: COMPARATOR
Intervention: Extended care treatment groups
Number of subjects: 144
Study 14581010 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-gated MCTA (n=25, group 1)
Number of subjects: 48
Study 14581010 — intervention group
Group type: COMPARATOR
Intervention: Non-ECG-gated MCTA (n=23, group 2)
Number of subjects: 48
Study 10711591 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills intervention
Number of subjects: 67
Study 10711591 — intervention group
Group type: COMPARATOR
Intervention: Disease-education control
Number of subjects: 67
Study 9229195 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, twice daily)
Number of subjects: 16
Study 9229195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9229195 — intervention group
Group type: COMPARATOR
Intervention: Acipimox and Placebo
Number of subjects: 16
Study 8250301 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 micrograms/kg
Number of subjects: 23
Study 8250301 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 60 micrograms/kg
Number of subjects: 23
Study 8250301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8250301 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (both doses)
Number of subjects: 23
Study 4041341 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg twice daily)
Number of subjects: 8
Study 4041341 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 8
Study 4041341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30483246 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches targeting myofibroblasts
Number of subjects: 0
Study 27389975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 (3, 6, 12, or 18 mg twice daily)
Number of subjects: 276
Study 27389975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 (12 and 18 mg)
Number of subjects: 276
Study 27389975 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-494 (6-18 mg)
Number of subjects: 276
Study 27389975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 24535356 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-involved digital design and esthetic outcome prediction using CAD and CAM techniques.
Number of subjects: 32
Study 24535356 — intervention group
Group type: COMPARATOR
Intervention: Control group used regular design method for restoration.
Number of subjects: 32
Study 22673191 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic information
Number of subjects: 396
Study 22673191 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-environment interaction information
Number of subjects: 396
Study 22673191 — intervention group
Group type: COMPARATOR
Intervention: Non-genetic (environment) information
Number of subjects: 396
Study 20582466 — intervention group
Group type: EXPERIMENTAL
Intervention: Pq1wC (paclitaxel 60 mg/m(2) days 1, 8, 15, carboplatin AUC 6 day 1 for every 3 weeks)
Number of subjects: 213
Study 20582466 — intervention group
Group type: COMPARATOR
Intervention: Pq3wC (paclitaxel 175 mg/m(2) day 1, carboplatin AUC 6 d1, every 3 weeks)
Number of subjects: 213
Study 18618000 — intervention group
Group type: EXPERIMENTAL
Intervention: Common susceptibility and protective haplotypes at the CHRNA5-A3-B4 locus
Number of subjects: 2827
Study 18618000 — intervention group
Group type: EXPERIMENTAL
Intervention: AA versus BC diplotype frequency
Number of subjects: 2827
Study 18618000 — intervention group
Group type: EXPERIMENTAL
Intervention: AA versus CC diplotype frequency
Number of subjects: 2827
Study 18618000 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic effect
Number of subjects: 2827
Study 15894954 — intervention group
Group type: EXPERIMENTAL
Intervention: Early use of a novel undergarment
Number of subjects: 430
Study 15894954 — intervention group
Group type: COMPARATOR
Intervention: Usual care of the institution
Number of subjects: 430
Study 12061945 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole 100 mg/day (50 mg b.i.d.)
Number of subjects: 516
Study 12061945 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 516
Study 11956263 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin‐RT (CRT) - cisplatin 40 mg/m² weekly for up to 8 weeks with radical RT
Number of subjects: 350
Study 11956263 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 350
Study 11956263 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent cisplatin‐RT (CRT)
Number of subjects: 350
Study 9714025 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdilution HDF (POD-HDF)
Number of subjects: 0
Study 9714025 — intervention group
Group type: EXPERIMENTAL
Intervention: Predilution HDF (PRD-HDF)
Number of subjects: 0
Study 9714025 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HD)
Number of subjects: 0
Study 7978475 — intervention group
Group type: EXPERIMENTAL
Intervention: TTSF-75 patch (75 micrograms/h)
Number of subjects: 120
Study 7978475 — intervention group
Group type: EXPERIMENTAL
Intervention: TTSF-50 patch (50 micrograms/h)
Number of subjects: 120
Study 7978475 — intervention group
Group type: EXPERIMENTAL
Intervention: TTSF-50 and TTSF-75 patches
Number of subjects: 120
Study 7978475 — intervention group
Group type: EXPERIMENTAL
Intervention: TTSF patches
Number of subjects: 120
Study 7978475 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 120
Study 7978475 — intervention group
Group type: EXPERIMENTAL
Intervention: TTSF-75 patch
Number of subjects: 120
Study 3173046 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg)
Number of subjects: 8
Study 3173046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31812719 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Gy × 5 fractions of precision radiation therapy
Number of subjects: 40
Study 31812719 — intervention group
Group type: COMPARATOR
Intervention: 4 Gy × 5 fractions (control group)
Number of subjects: 40
Study 31551314 — intervention group
Group type: EXPERIMENTAL
Intervention: BEAMing
Number of subjects: 363
Study 31551314 — intervention group
Group type: EXPERIMENTAL
Intervention: ddPCR
Number of subjects: 363
Study 31551314 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 363
Study 27518833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolaevulinate (MAL) and intense pulsed light (IPL)
Number of subjects: 37
Study 27518833 — intervention group
Group type: COMPARATOR
Intervention: Placebo and intense pulsed light (IPL)
Number of subjects: 37
Study 25497513 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering treatment (target SBP <140 mmHg within 1 hour)
Number of subjects: 2839
Study 25497513 — intervention group
Group type: COMPARATOR
Intervention: Guideline‐recommended blood pressure lowering treatment (target SBP <180 mmHg)
Number of subjects: 2839
Study 23866184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 452
Study 23866184 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful microcirculatory reperfusion (MBG 2/3)
Number of subjects: 452
Study 21790298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medikinet retard (50% immediate release)
Number of subjects: 113
Study 21790298 — intervention group
Group type: EXPERIMENTAL
Intervention: Medikinet retard (lower daily dose, similar IR components in the morning)
Number of subjects: 113
Study 21790298 — intervention group
Group type: COMPARATOR
Intervention: Concerta (22% immediate release)
Number of subjects: 113
Study 18052991 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic skin response (GSR) during painful stimulation
Number of subjects: 32
Study 18052991 — intervention group
Group type: EXPERIMENTAL
Intervention: Premature infant pain profile (PIPP) during painful stimulation
Number of subjects: 32
Study 18052991 — intervention group
Group type: COMPARATOR
Intervention: Galvanic skin response (GSR) and PIPP
Number of subjects: 32
Study 16627305 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 16627305 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 0
Study 16627305 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Methadone
Number of subjects: 0
Study 14619197 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended transthoracic resection
Number of subjects: 0
Study 14619197 — intervention group
Group type: COMPARATOR
Intervention: Transhiatal resection
Number of subjects: 0
Study 10885046 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for males and 0.5 g/kg for females)
Number of subjects: 18
Study 10885046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8816142 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐α (IFN‐α)
Number of subjects: 240
Study 1553858 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (intervention to suppress renal prostaglandins)
Number of subjects: 10
Study 1553858 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 10
Study 31874891 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivised-peer-networks
Number of subjects: 12000
Study 31874891 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-navigator-distribution
Number of subjects: 12000
Study 31874891 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 12000
Study 29898169 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipchart (serial album) used in intervention group (IG)
Number of subjects: 112
Study 29898169 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 112
Study 26484950 — intervention group
Group type: EXPERIMENTAL
Intervention: IRB members
Number of subjects: 694
Study 26484950 — intervention group
Group type: COMPARATOR
Intervention: Transplant surgeons and OPO professionals
Number of subjects: 694
Study 24842596 — intervention group
Group type: EXPERIMENTAL
Intervention: Year-framed message (associated with lower levels of snacking)
Number of subjects: 95
Study 24842596 — intervention group
Group type: COMPARATOR
Intervention: Day-framed message
Number of subjects: 95
Study 22502839 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) 30min per day, 5 days per week for 12 weeks (n=37)
Number of subjects: 76
Study 22502839 — intervention group
Group type: COMPARATOR
Intervention: Control group without TEAS treatment (n=39)
Number of subjects: 76
Study 22502839 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 76
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated knee extension
Number of subjects: 19
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight leg raise
Number of subjects: 19
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on one leg
Number of subjects: 19
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction
Number of subjects: 19
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring activation
Number of subjects: 19
Study 19486478 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercises tested
Number of subjects: 19
Study 17361105 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP90 inhibitor 17-allylaminogeldanamycin
Number of subjects: 0
Study 17361105 — intervention group
Group type: EXPERIMENTAL
Intervention: RACK1
Number of subjects: 0
Study 16475452 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic glass
Number of subjects: 18
Study 16475452 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw
Number of subjects: 18
Study 16475452 — intervention group
Group type: COMPARATOR
Intervention: Directly from bottle
Number of subjects: 18
Study 11899948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg after a high-fat meal
Number of subjects: 24
Study 11899948 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg after fasting
Number of subjects: 24
Study 10365903 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group with polypectomy
Number of subjects: 799
Study 10365903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 799
Study 10365903 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 799
Study 7572695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 4159
Study 7572695 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4159
Study 1675520 — intervention group
Group type: EXPERIMENTAL
Intervention: Flagellum ELISA
Number of subjects: 200
Study 1675520 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture ELISA
Number of subjects: 200
Study 1675520 — intervention group
Group type: COMPARATOR
Intervention: IgM Western blot
Number of subjects: 200
Study 1675520 — intervention group
Group type: COMPARATOR
Intervention: IgG Western blot
Number of subjects: 200
Study 7341547 — intervention group
Group type: EXPERIMENTAL
Intervention: d,1-Carnitine (3 g/daily)
Number of subjects: 20
Study 30308560 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy (0.1-mL subretinal injection of 10 genome particles)
Number of subjects: 6
Study 30308560 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV2-REP1 gene therapy
Number of subjects: 6
Study 30308560 — intervention group
Group type: COMPARATOR
Intervention: Control eyes
Number of subjects: 6
Study 30562305 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week resistance training (RT) intervention
Number of subjects: 23
Study 30562305 — intervention group
Group type: COMPARATOR
Intervention: Usual care waitlist control group
Number of subjects: 23
Study 28386035 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 7020